Market-Weighted Healthcare or Active Manager Selection? IYH vs. PINK

Simplify Health Care ETF (PINK) has outperformed iShares U.S. Healthcare ETF (IYH) over the past year, returning 29.30% versus 15.30%, but it charges a higher 0.51% expense ratio and offers a lower 0.66% dividend yield. IYH remains the lower-cost, higher-yield option at 0.38% expense ratio and 1.28% yield, with less volatility as shown by its lower beta of 0.57 versus 0.74 for PINK. The article frames the decision as a choice between IYH’s broad passive exposure to 102 healthcare stocks and PINK’s more concentrated, active, mission-driven strategy.

Analysis

The core signal is not “healthcare outperformed,” but that active stock selection is being rewarded only inside a narrow innovation sleeve. PINK’s outperformance is likely being driven by a small number of idiosyncratic winners in obesity, specialty biotech, and selected med-tech exposure; that creates a lot more path dependency than the wrapper suggests. By contrast, IYH’s lower beta and higher yield imply it behaves more like a defensive cash-flow basket, so the spread between the two is really a barbell between factor momentum and balance-sheet quality.

Second-order, the most crowded profit pool is probably not the ETF itself but the underlying large-cap constituents in IYH. When passive flows dominate, mega-caps like JNJ, ABBV, and especially LLY become de facto liquidity sinks, which can mute valuation dispersion but also cap upside if earnings revisions slow. The more interesting opportunity is in UTHR and NVO: both have enough idiosyncratic growth to benefit from an active fund’s concentration, but they are less “owned by default” than the large defensive names, so incremental flow can matter more.

The risk to PINK’s relative run is mean reversion from concentration and style rotation. If rates back up or biotech funding tightens, the market will punish long-duration healthcare innovation faster than diversified pharma, and PINK’s higher beta can cut both ways over a 3-6 month horizon. Conversely, if policy headlines re-rate drug-pricing risk lower or obesity/gene-therapy momentum persists, IYH likely lags because its weights are anchored to slower growers rather than the highest-conviction themes.

Consensus is treating this as a simple active-vs-passive debate, but the real miss is that the “active” vehicle is effectively a venture-beta proxy inside a defensive sector. That means the right question is not which ETF is cheaper, but which regime dominates over the next two quarters: macro defensiveness or innovation scarcity premium. The philanthropic overlay is reputationally positive but economically irrelevant; the market is paying for concentrated factor exposure, not mission alignment.

Key Decisions for Investors

• Long PINK / short IYH as a 3-6 month relative-value pair only if biotech breadth remains firm; target 8-12% spread capture with a tight stop if healthcare leadership rotates back to defensives.
• Prefer direct long exposure to UTHR over the ETF wrapper for a 6-12 month horizon; it offers cleaner upside to specialty-care volume growth with less dilution from low-conviction holdings.
• Use IYH as the defensive hedge leg against growth-heavy healthcare and biotech exposure; it should outperform in a rates-up or risk-off tape, with lower drawdown than PINK.
• Avoid chasing PINK after a strong 12-month run unless you expect continued momentum in obesity/gene-therapy names; the concentration means a single constituent reversal can erase several quarters of ETF alpha.